RemeGen Co Ltd - ESG Rating & Company Profile powered by AI
If you are employed by RemeGen Co Ltd and you wish to licence your ESG aseessment, please contact us. Alternative companies in the rating industry group for RemeGen Co Ltd are shown below. The report of RemeGen Co Ltd was prepared by All Street Sevva using cutting edge NLP.
RemeGen Co Ltd in the Pharmaceuticals industry gained a UN SDG ESG Transparency Score of 1.7; made up of an environmental score of 0.0, social score of 1.1 and governance score of 4.0.
1.7
Low ImpactEnvironmental
Social
Governance
Peer Group Comparison
| Rank | Company | SDG Transparency Score ⓘ | Performance |
|---|---|---|---|
| 1 | Caladrius Biosciences Inc | 8.0 | High |
| 1 | Can Fite Biopharma Ltd | 8.0 | High |
| ... | ... | ... | |
| 1631 | Viewbix Inc | 1.8 | Low |
| 1631 | dorsaVi Ltd | 1.8 | Low |
| 1682 | RemeGen Co Ltd | 1.7 | Low |
| 1682 | C4 Therapeutics Inc | 1.7 | Low |
| 1682 | Abcellera Biologics Inc | 1.7 | Low |
| 1970 | Zyden Gentec Ltd | 0.0 | Low |
| 1970 | iNtRON Biotechnology Inc | 0.0 | Low |
| ... | ... | ... |
Frequently Asked Questions
Does RemeGen Co Ltd have an accelerator or VC vehicle to help deliver innovation?
Sign up for free to unlockDoes RemeGen Co Ltd disclose current and historical energy intensity?
Sign up for free to unlockDoes RemeGen Co Ltd report the average age of the workforce?
Sign up for free to unlockDoes RemeGen Co Ltd reference operational or capital allocation in relation to climate change?
Sign up for free to unlockDoes RemeGen Co Ltd disclose its ethnicity pay gap?
Sign up for free to unlockDoes RemeGen Co Ltd disclose cybersecurity risks?
Sign up for free to unlockDoes RemeGen Co Ltd offer flexible work?
Sign up for free to unlockDoes RemeGen Co Ltd have a long term incentive (LTI) executive compensation plan based on a measure of return on capital?
Sign up for free to unlockDoes RemeGen Co Ltd disclose the number of employees in R&D functions?
Sign up for free to unlockDoes RemeGen Co Ltd conduct supply chain audits?
Sign up for free to unlockDoes RemeGen Co Ltd disclose incidents of non-compliance in relation to the health and safety impacts of products and services?
Sign up for free to unlockIs there a statment that there is no plan to expand their cement production? (for example: 'We have no current plans to add additional cement making capacity')
Sign up for free to unlockDoes RemeGen Co Ltd conduct 360 degree staff reviews?
Sign up for free to unlockDoes RemeGen Co Ltd disclose the individual responsible for D&I?
Sign up for free to unlockDoes RemeGen Co Ltd disclose current and historical air emissions?
Sign up for free to unlockIs there a statment that there is no plan to expand their coal usage? (for example: 'We have no current plans to add additional coal powered electricity generation')
Sign up for free to unlockIs executive remuneration linked to climate performance?
Sign up for free to unlockDoes the Board describe its role in the oversight of climate-related risks and opportunities?
Sign up for free to unlockDoes RemeGen Co Ltd disclose current and / or historical scope 2 emissions?
Sign up for free to unlockDoes RemeGen Co Ltd disclose water use targets?
Sign up for free to unlockDoes RemeGen Co Ltd have careers partnerships with academic institutions?
Sign up for free to unlockDid RemeGen Co Ltd have a product recall in the last two years?
Sign up for free to unlockDoes RemeGen Co Ltd disclose incidents of discrimination?
Sign up for free to unlockDoes RemeGen Co Ltd allow for Work Councils/Collective Agreements to be formed?
Sign up for free to unlockHas RemeGen Co Ltd issued a profit warning in the past 24 months?
Sign up for free to unlockDoes RemeGen Co Ltd disclose parental leave metrics?
Sign up for free to unlockDoes RemeGen Co Ltd disclose climate scenario or pathway analysis?
Sign up for free to unlockDoes RemeGen Co Ltd disclose current and / or historical scope 1 emissions?
Sign up for free to unlockAre Operating Expesnses linked to emissions reduction?
Sign up for free to unlockDoes RemeGen Co Ltd disclose the pay ratio of women to men?
Sign up for free to unlockDoes RemeGen Co Ltd support suppliers with sustainability related research and development?
Sign up for free to unlockDoes RemeGen Co Ltd disclose the number of operations that have been subject to human rights reviews or human rights impact assessments?
Sign up for free to unlockDoes RemeGen Co Ltd reflect climate-related risks in its financial statements?
Sign up for free to unlockIs there a statment that there is no plan to expand their carbon intensite energy assets? (for example: 'We have no current plans to carry out further drilling for oil,')
Sign up for free to unlockIs RemeGen Co Ltd involved in embryonic stem cell research?
Sign up for free to unlockDoes RemeGen Co Ltd disclose GHG and Air Emissions intensity?
Sign up for free to unlockDoes RemeGen Co Ltd disclose its waste policy?
Sign up for free to unlockDoes RemeGen Co Ltd report according to TCFD requirements?
Sign up for free to unlockDoes RemeGen Co Ltd disclose its policies for bribery, corruption, whistle-blower, conflict of interest?
Sign up for free to unlockDoes RemeGen Co Ltd disclose energy use targets?
Sign up for free to unlockDoes RemeGen Co Ltd disclose its Renewable Energy targets?
Subscription requiredAre emissions metrics verified by STBi?
Subscription requiredDoes RemeGen Co Ltd have a policy relating to cyber security?
Sign up for free to unlockHave a different question?
Potential Risks for RemeGen Co Ltd
These potential risks are based on the size, segment and geographies of the company.
RemeGen Co., Ltd., a biopharmaceutical company, engages in the discovery, development, and commercialization of biologics for the treatment of autoimmune, oncology, and ophthalmic diseases with unmet medical needs in Mainland China and the United States. The company offers Telitacicept (RC18) for use in the treatment of systemic lupus erythematosus an autoimmune disease and Disitamab Vedotin (RC48) for use in the treatment of various cancers. Its products in various stages of development include RC18, which is under phase III clinical trials for the treatment of neuromyelitis optica spectrum disorder and rheumatoid arthritis, and phase II clinical trials for the treatment of IgA nephritis, Sjögren's syndrome, multiple sclerosis, and myasthenia gravis; RC28, which has completed Phase 1 clinical trials for use in the treatment of wet age-related macular degeneration, diabetic macular edema, and diabetic retinopathy; RC98, a PD-L1 monoclonal antibody for the treatment of solid tumors and is under Phase I clinical trial; RC88, which is in Phase 1 clinical trials for use in the treatment of mesothelioma, bile duct carcinoma, pancreatic cancer, ovarian carcinoma, lung adenocarcinoma, and other solid tumors, as well as lung and urothelial cancer; and RC108 that is in Phase 1 clinical trials to treat various solid tumors. In addition, the company's products under pre-clinical development include RC118, RC138, RC148, RC158, RC168, RC178, RC188, and RC198 to treat various solid tumors; and RC208, RC218, and RC228 to treat ophthalmic diseases. RemeGen Co., Ltd. was incorporated in 2008 and is headquartered in Yantai, the People's Republic of China.